57.29
price down icon2.55%   -1.50
pre-market  Pre-market:  58.99   1.70   +2.97%
loading
Halozyme Therapeutics Inc stock is traded at $57.29, with a volume of 1.27M. It is down -2.55% in the last 24 hours and down -12.08% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$58.79
Open:
$58.74
24h Volume:
1.27M
Relative Volume:
0.92
Market Cap:
$7.58B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
18.97
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
-6.68%
1M Performance:
-12.08%
6M Performance:
+10.66%
1Y Performance:
+48.27%
1-Day Range:
Value
$56.47
$58.99
1-Week Range:
Value
$56.47
$62.14
52-Week Range:
Value
$37.97
$66.00

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
Name
Halozyme Therapeutics Inc
Name
Phone
(858) 794-8889
Name
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
Employee
350
Name
Twitter
@halozymeinc
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
HALO's Discussions on Twitter

Compare HALO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HALO
Halozyme Therapeutics Inc
57.29 7.58B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-07-24 Downgrade Wells Fargo Overweight → Equal Weight
Sep-19-24 Downgrade JP Morgan Overweight → Neutral
Jun-07-24 Downgrade Piper Sandler Overweight → Neutral
Feb-29-24 Initiated TD Cowen Outperform
Jul-24-23 Downgrade Goldman Buy → Neutral
Jul-24-23 Initiated H.C. Wainwright Buy
May-10-23 Upgrade Piper Sandler Neutral → Overweight
Mar-27-23 Resumed Berenberg Buy
Mar-16-23 Downgrade SVB Securities Outperform → Market Perform
Dec-21-22 Resumed Morgan Stanley Overweight
Nov-28-22 Initiated Wells Fargo Overweight
Sep-09-22 Initiated Morgan Stanley Overweight
May-23-22 Initiated SVB Leerink Outperform
Jun-14-21 Initiated Evercore ISI Outperform
May-17-21 Initiated SVB Leerink Outperform
May-11-21 Downgrade Piper Sandler Overweight → Neutral
Jan-21-21 Reiterated The Benchmark Company Buy
Dec-17-20 Initiated Berenberg Buy
Sep-14-20 Resumed JP Morgan Overweight
Jul-01-20 Initiated The Benchmark Company Buy
Feb-05-20 Upgrade Piper Sandler Neutral → Overweight
Jan-09-20 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-08-20 Initiated Goldman Buy
Nov-05-19 Upgrade Barclays Underweight → Equal Weight
Oct-19-18 Resumed Piper Jaffray Neutral
May-11-18 Downgrade Barclays Equal Weight → Underweight
Jan-24-18 Initiated Goldman Neutral
Oct-16-17 Reiterated Piper Jaffray Overweight
Jan-06-17 Downgrade Citigroup Buy → Neutral
Nov-03-16 Initiated Deutsche Bank Buy
Dec-04-15 Initiated Wells Fargo Outperform
Nov-18-15 Initiated Citigroup Buy
Sep-22-15 Initiated Barclays Overweight
Jun-22-15 Reiterated JP Morgan Overweight
Mar-03-15 Reiterated UBS Buy
Feb-18-15 Reiterated MLV & Co Buy
Jan-08-15 Reiterated MLV & Co Buy
View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

pulisher
Apr 20, 2025

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st

Apr 20, 2025
pulisher
Apr 16, 2025

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity - Yahoo Finance

Apr 16, 2025
pulisher
Apr 11, 2025

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market - MSN

Apr 11, 2025
pulisher
Apr 11, 2025

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Pre - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Argenx stock rises on FDA nod for Vyvgart Hytrulo (ARGX) - Seeking Alpha

Apr 11, 2025
pulisher
Apr 11, 2025

Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx - marketscreener.com

Apr 11, 2025
pulisher
Apr 10, 2025

Halozyme :FDA Oks Argenx' VYVGART Hytrulo Prefilled Syringe For Generalized Myasthenia Gravis & CIDP - Nasdaq

Apr 10, 2025
pulisher
Apr 10, 2025

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - Citizen Tribune

Apr 10, 2025
pulisher
Apr 10, 2025

J&J, Halozyme win EU nod for injectable Rybrevant in lung cancer - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewswire Inc.

Apr 10, 2025
pulisher
Apr 10, 2025

Game-Changing FDA Approval: New Self-Injectable Treatment Transforms Rare Disease Care - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Halozyme Therapeutics (HALO) Gains EU Approval for Injectable Co - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma - Seeking Alpha

Apr 09, 2025
pulisher
Apr 09, 2025

European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Halozyme Reports EC Approval For Indication Extension Of DARZALEX Co-formulated With ENHANZE - Nasdaq

Apr 09, 2025
pulisher
Apr 09, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Quantisnow

Apr 09, 2025
pulisher
Apr 08, 2025

Halozyme Therapeutics : Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing 's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Bre - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Halozyme Therapeutics : To Receive $10 Million Milestone Payment From Janssen - MarketScreener

Apr 08, 2025
pulisher
Apr 07, 2025

Halozyme (HALO) Secures European Approval for J&J Antitumor Inje - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve

Apr 07, 2025
pulisher
Apr 07, 2025

Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

EC approves new lung cancer treatment using Halozyme technology - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener

Apr 07, 2025
pulisher
Apr 03, 2025

KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Apr 03, 2025
pulisher
Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

4,812 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by EntryPoint Capital LLC - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Long Term Trading Analysis for (HALO) - news.stocktradersdaily.com

Mar 31, 2025
pulisher
Mar 31, 2025

Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications - Quantisnow

Mar 31, 2025
pulisher
Mar 31, 2025

Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters

Mar 27, 2025
pulisher
Mar 27, 2025

Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat

Mar 27, 2025
pulisher
Mar 26, 2025

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 26, 2025
pulisher
Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance

Mar 24, 2025
pulisher
Mar 21, 2025

Halozyme Announces Retirement of Chief Technical Officer - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme announces CTO retirement, effective immediately - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Drug developers show mixed performance in early 2025 - BioWorld MedTech

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme Joins the $1 Billion Club - Yahoo Finance

Mar 21, 2025
pulisher
Mar 17, 2025

AstraZeneca signs $1.35B Alteogen deal for subcutaneous cancer drugs - Fierce Pharma

Mar 17, 2025
pulisher
Mar 14, 2025

Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha

Mar 14, 2025

Halozyme Therapeutics Inc Stock (HALO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Cap:     |  Volume (24h):